Medpace Q2 revenue beats estimates
Overview
Medpace Q2 2025 revenue up 14.2% to $603.3 mln, beating analyst expectations
Clinical contract research organization's GAAP net income for Q2 rises to $90.3 mln, with net income margin of 15.0%
Company repurchased 1.75 mln shares for a total of $518.5 mln in Q2 2025
Outlook
Medpace forecasts 2025 revenue between $2.420 bln and $2.520 bln
Company expects full-year GAAP net income of $405 mln to $428 mln
Medpace sees 2025 diluted EPS ranging from $13.76 to $14.53
Result Drivers
BACKLOG CONVERSION - Revenue growth represents a backlog conversion rate of 21.2%
NET NEW BUSINESS - Increase in net new business awards to $620.5 mln contributed to revenue growth
COST INCREASES - Higher direct costs and SG&A expenses impacted net income margin
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $603.31 mln | $538.80 mln (9 Analysts) |
Q2 Net Income | $90.26 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Medpace Holdings Inc is $300.00, about 4% below its July 18 closing price of $311.87
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 24 three months ago
Press Release:
